Neuroimmunology

“This study offers hope to patients, since each attack in NMO can cause loss of visual or motor function,” says Sean Pittock, M.D., a Mayo Clinic neurologist and first author.

By Mayo Clinic News Network • May 3, 2019

PACE / State of CA / State of FL
This “Specialty Testing” webinar will discuss the diagnosis, pathological understanding, and current best treatment options for necrotizing autoimmune myopathy.

By MCL Education • January 31, 2019

This week’s Research Roundup highlights pathogenic implications of cerebrospinal fluid barrier pathology in neuromyelitis optica.

By Kelley Luedke • February 20, 2017

Greg Widseth was suddenly hit by a rare disease that prompted his immune system to attack his brain cells, resulting in as many as 60 seizures a day. Special blood and spinal fluid tests developed by Mayo Medical Laboratories confirmed that Widseth had antibodies known to target certain brain cells.

By mayocliniclabs • December 20, 2016

In this “Hot Topic,” Sean Pittock, M.D., introduces a new FACS Assay for detection of Aquaporin4-IgG discovered in the lab, which is required for the diagnosis of neuromyelitis optica spectrum disorders and allows for distinction from multiple sclerosis.

By MCL Education • October 3, 2016

Mayo Clinic researchers conducted a study to characterize the clinical features and MRI abnormalities of leucine-rich glioma-inactivated 1 (LGI1)-autoantibody (Ab) faciobrachial dystonic seizures. The study was recently published in the Neurology: Neuroimmunology & Neuroinflammation journal.

By Kelley Luedke • November 18, 2015

Multiple system atrophy is a sporadic alpha-synucleinopathy that typically affects patients in their sixth decade of life and beyond. Pathologically, it is characterized by glial cytoplasmic inclusions containing filamentous alpha-synuclein, but neuronal inclusions have also been reported but remain less well defined. Mayo Clinic researchers conducted a study published in the journal Brain to further define the spectrum of neuronal pathology.

By Kelley Luedke • June 16, 2015

Greg Widseth, a 47-year old Polk County attorney, was suddenly hit by a rare disease that prompted his immune system to attack his brain cells, resulting in as many as 60 seizures a day. Special blood and spinal fluid tests developed by Mayo Medical Laboratories confirmed that Widseth had antibodies known to target certain brain cells. Read the full article to learn more about autoimmune disorder testing and treatment.

By Kelley Luedke • March 22, 2015

Short transverse myelitis is considered non-characteristic of neuromyelitis optica (NMO) spectrum disorders (NMOSDs). Mayo Clinic researchers conducted a study, recently published in Jama Neurology, to determine the frequency of short lesions at the initial myelitis manifestation of NMOSD and to compare the demographic, clinical, and radiological characteristics of aquaporin-4-IgG (AQP4-IgG) seropositive and seronegative STM.

By Kelley Luedke • December 3, 2014

A recent article in The New York Times reported on celiac disease, an autoimmune disorder of the gut triggered by the gluten proteins in wheat and other grains, and its connection to the human brain. Upon analysis of several cases, treating an autoimmune disease of the gut (by avoiding gluten) resolved what looked like a debilitating disorder of the brain.

By Kelley Luedke • October 13, 2014

A new dementia autoimmune evaluation is now available. View this post to learn what providers should know about autoimmune dementia, our testing approach, as well as interpretation, follow-up, and additional considerations once the test has been ordered.

By brentwestra • July 30, 2014

A new encephalopathy autoimmune evaluation is now available. View this post to learn what providers should know about autoimmune encephalopathy, our testing approach, as well as interpretation, follow-up, and additional considerations once the test has been ordered.

By brentwestra • July 21, 2014

A new epilepsy autoimmune evaluation is now available. View this post to learn what providers should know about autoimmune epilepsy, our testing approach, as well as interpretation, follow-up, and additional considerations once the test has been ordered.

By brentwestra • July 10, 2014